MET and melanoma: These results are in line with a recent study in melanoma, where it was demonstrated that HGF/MET signaling contributed to resistance to the BRAF inhibitor vemurafenib via activation of ERK-MAPK and PI3K-AKT, and that pharmacologic inhibition of the cMet/AKT pathway restored the sensitivity (37).